These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 11104551)

  • 21. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.
    Wilson WR; Denny WA; Pullen SM; Thompson KM; Li AE; Patterson LH; Lee HH
    Br J Cancer Suppl; 1996 Jul; 27():S43-7. PubMed ID: 8763844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The Oxygen effect: an old new target?].
    Lartigau E; Dewas S; Gras L
    Cancer Radiother; 2008 Jan; 12(1):42-9. PubMed ID: 18261946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor hypoxia in cancer therapy.
    Brown JM
    Methods Enzymol; 2007; 435():297-321. PubMed ID: 17998060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
    Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radioprotection: the non-steroidal anti-inflammatory drugs (NSAIDs) and prostaglandins.
    Lee TK; Stupans I
    J Pharm Pharmacol; 2002 Nov; 54(11):1435-45. PubMed ID: 12495545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
    Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
    Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts.
    Wilson WR; Tercel M; Anderson RF; Denny WA
    Anticancer Drug Des; 1998 Sep; 13(6):663-85. PubMed ID: 9755724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N.
    Gallagher R; Hughes CM; Murray MM; Friery OP; Patterson LH; Hirst DG; McKeown SR
    Br J Cancer; 2001 Aug; 85(4):625-9. PubMed ID: 11506506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N).
    Mehibel M; Singh S; Chinje EC; Cowen RL; Stratford IJ
    Mol Cancer Ther; 2009 May; 8(5):1261-9. PubMed ID: 19435866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiation sensitization with redox modulators: a promising approach.
    Rosenberg A; Knox S
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):343-54. PubMed ID: 16414370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone.
    Manley E; Waxman DJ
    J Pharmacol Exp Ther; 2013 Feb; 344(2):368-77. PubMed ID: 23192656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiation enhances the therapeutic effect of Banoxantrone in hypoxic tumour cells with elevated levels of nitric oxide synthase.
    Mehibel M; Singh S; Cowen RL; Williams KJ; Stratford IJ
    Oncol Rep; 2016 Apr; 35(4):1925-32. PubMed ID: 26782976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria.
    Lehouritis P; Stanton M; McCarthy FO; Jeavons M; Tangney M
    J Control Release; 2016 Jan; 222():9-17. PubMed ID: 26655063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1.
    Nishida CR; Lee M; de Montellano PR
    Mol Pharmacol; 2010 Sep; 78(3):497-502. PubMed ID: 20566689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
    Phillips RM
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of AQ4N and its reduction product on radiation-mediated DNA strand breakage.
    Ali MM; Symons MC; Taiwo FA; Patterson LH
    Chem Biol Interact; 1999 Nov; 123(1):1-10. PubMed ID: 10597898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
    Denny WA
    Future Oncol; 2010 Mar; 6(3):419-28. PubMed ID: 20222798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the molecular basis for tumour hypoxia.
    Carroll VA; Ashcroft M
    Expert Rev Mol Med; 2005 Apr; 7(6):1-16. PubMed ID: 15831177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Can tumor hypoxia be turned into a chemotherapeutic advantage?].
    Trédan O; Grantab R; Dumontet C
    Bull Cancer; 2008 May; 95(5):528-34. PubMed ID: 18541517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.